Scott Guerin, PhD

Clinical Pathways GPS

Looking for Leadership in Developing Pathways

10/16/2017

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Scott Guerin, PhD

A clinical pathway can be defined as an “optimal sequencing and timing of interventions by physicians, nurses, and other staff for a particular diagnosis or procedure.” As organizations new to pathways look to...

A...

10/16/2017

Journal of Clinical Pathways

Clinical Pathways GPS

Truly Patient-Centered Clinical Pathways

08/16/2017

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Scott Guerin, PhD

For clinical pathways to be most effective, they need to accommodate many external factors impacting patients. These include issues such as the social determinants of health, as well as access to care that can impact...

For...

08/16/2017

Journal of Clinical Pathways

Clinical Pathways GPS

The New FDA and Its Impact on Clinical Pathways

06/14/2017

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Scott Guerin, PhD

President Donald J Trump’s selection of Scott Gottlieb, MD, to lead the Food and Drug Administration (FDA) has ushered in a new direction for the government agency, which is likely to alter the availability and use...

...

06/14/2017

Journal of Clinical Pathways

Special Article

Diabetes Clinical Pathways: Going Beyond Treatment Decisions

12/09/2016

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Scott Guerin, PhD

Diabetes guidelines increasingly go beyond treatment recommendations to take into account quality measures for diabetes care that exist within new value-based systems, addressing the roles and responsibilities of...

...

12/09/2016

Journal of Clinical Pathways

Clinical Pathways GPS

The Future of Clinical Pathways: The Potential Impact of the Presidential Election

10/12/2016

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Scott Guerin, PhD

Although the topic of health care will continue to be a political one, the continued growth of public health care spending suggests that the government will need to continue its shift toward improving the value of...

...

10/12/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Population Health Delivery Through Health Systems and Pharma

09/06/2016

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Scott Guerin, PhD

As health systems become more prevalent, they are having increasing levels of control over treatment decisions, in coordination with physicians and managed care organizations. As a result of this increased level of...

As...

09/06/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Hitting Each Component of the Triple Aim Along the Clinical Pathway

05/06/2016

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Scott Guerin, PhD

Seth Gordon, MBA

The concept of the Triple Aim—improving the experience of care, reducing the costs of care, and improving the health of populations—is increasingly becoming important to drug manufacturers, who must demonstrate how...

The...

05/06/2016

Journal of Clinical Pathways

Perspectives

Impact of Government Cost Controls on Treatment Selection for Clinical Pathways

03/08/2016

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Scott Guerin, PhD

Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...

...

03/08/2016

Journal of Clinical Pathways

Clinical Pathways GPS

The Role of Patient Adherence in Successful Clinical Pathway Implementation

02/16/2016

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Scott Guerin, PhD

When considering the development of clinical pathways, the pathway itself is only the beginning; optimum outcomes cannot be realized unless patients follow their prescribed treatments. Simply having prescribers write...

When...

02/16/2016

Journal of Clinical Pathways

Clinical Pathways GPS

The Place for Biosimilars in Clinical Pathways

12/14/2015

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Scott Guerin, PhD

Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...

Payers...

12/14/2015

Journal of Clinical Pathways